



ASX Announcement

23 September 2022

Date of AGM and Closing Date for Director Nominations

In accordance with ASX Listing Rule 3.13.1, **Invex Therapeutics Limited** (ASX: IXC) (**Company**) advises that the Annual General Meeting of the Company will be held on Tuesday, 22 November 2022.

A notice of meeting for the Annual General Meeting is being prepared by the Company and will be announced to ASX and provided to Shareholders in October 2022.

An item of business at the Annual General Meeting will be the election of Directors. The closing date for the receipt of nominations for the election of Directors is Friday, 7 October 2022.

Any nominations must be received no later than 5:00pm (Perth time) on Friday, 7 October 2022 at the Company's registered office.

This release dated 23 September has been authorised for lodgement to the ASX by Narelle Warren, Company Secretary

ENDS

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

About Idiopathic Intracranial Hypertension (IIH)

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

About Presendin™

Presendin™ is a once per week, sub-cutaneous, sustained-release (SR) Exenatide microsphere formulation originally developed by Pepton, Inc. (KOSDAQ: 087010). In September 2021 Invex entered into an exclusive collaboration, manufacturing and supply agreement with Pepton for Presendin™ in IIH for all major markets, with the exception of South Korea.

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which is currently approved for the treatment of type 2 diabetes. In 2017, Invex received orphan drug designation for Exenatide in IIH from the US Food and Drug Administration and European Medicines Agency.

About the IIH EVOLVE Clinical Trial

The Phase III IIH EVOLVE trial is a randomised, placebo-controlled, double-blind, multi-centre trial that will randomise 240 patients with newly diagnosed IIH to determine the efficacy and safety of Presendin™ versus placebo, administered once weekly. Patients with a confirmed diagnosis of IIH will be randomised on a 1:1 basis to either Presendin™ or placebo for 24 weeks.

The primary endpoint of the trial is the change in intracranial pressure (ICP), as measured by lumbar puncture, at baseline and at 24 weeks. Secondary endpoints include the change in perimetric mean deviation (PMD), papilloedema and monthly headache days over 24 weeks.

IIH EVOLVE is designed to meet the requirements for market approval of Presendin™ for the treatment of Idiopathic Intracranial Hypertension (IIH) in the European Union (EU), United Kingdom (UK) and Australia.

Further study details can be found at [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT05347147) website under Identifier **NCT05347147** or by visiting: <https://clinicaltrials.gov/ct2/show/NCT05347147>.